Wednesday, 11 May 2016

Global Idiopathic Pulmonary Fibrosis Market 2016-2020

About Idiopathic Pulmonary Fibrosis Idiopathic pulmonary fibrosis belongs to a group of lung diseases known as interstitial lung diseases. It affects people in the age group 50-70 years. Diagnosis is effected by the exclusion of other interstitial lung diseases. High-resolution computed tomography (CT) is often employed to confirm the presence of the disease. There is no permanent cure for this disease; therefore, treatment involves relieving underlying symptoms. Nintedanib and pirfenidone are the two approved drugs for the treatment of idiopathic pulmonary fibrosis. Corticosteroids and...more >>

from Infiniti Research Limited Market Research Reports